Federico Maurizio
National Center for Global Health, Istituto Superiore di Sanità, Viale Regina Elena, 299, 00161, Rome, Italy.
Cytokine Growth Factor Rev. 2021 Aug;60:46-51. doi: 10.1016/j.cytogfr.2021.03.001. Epub 2021 Mar 6.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has given rise to the urgent need for vaccines and therapeutic interventions to address the spread of the SARS-CoV-2 virus. SARS-CoV-2 vaccines in development, and those being distributed currently, have been designed to induce neutralizing antibodies using the spike protein of the virus as an immunogen. However, the immunological correlates of protection against the virus remain unknown. This raises questions about the efficacy of current vaccination strategies. In addition, safety profiles of several vaccines seem inadequate or have not yet been evaluated under controlled experimentation. Here, evidence from the literature regarding the efforts already made to identify the immunological correlates of protection against SARS-CoV-2 infection are summarized. Furthermore, key biological features of most of the advanced vaccines and considerations regarding their safety and expected efficacy are highlighted.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）大流行引发了对疫苗和治疗性干预措施的迫切需求，以应对SARS-CoV-2病毒的传播。正在研发以及目前正在分发的SARS-CoV-2疫苗，设计为使用病毒的刺突蛋白作为免疫原诱导中和抗体。然而，针对该病毒的保护性免疫相关因素仍不清楚。这引发了关于当前疫苗接种策略有效性的问题。此外，几种疫苗的安全性似乎不足，或者尚未在对照实验中进行评估。在此，总结了文献中关于已为确定针对SARS-CoV-2感染的保护性免疫相关因素所做努力的证据。此外，还强调了大多数先进疫苗的关键生物学特性以及有关其安全性和预期疗效的考量。
